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Abstract: Genome-wide association studies revealed chromosome
regions 15q24-25 were associated with a higher risk for develop-
ment of lung cancer. The 15q24-25 region encompasses the nicotinic
acetylcholine receptor subunit genes (nAchR 3, 5, and 4) that
play a role in nicotine addiction. This review reports information of
the acetylcholine receptor and lung cancer. In patients diagnosed
with smoking-related lung cancer and who continue smoking, a
negative correlation with lung cancer survival has been shown. The
reduced treatment efficacy may well be explained by the pluriform
effect of nicotine on tumor cell proliferation, apoptosis, epitheli-
almesenchymal transition, proinvasive, and angiogenic effects,
which are reenforced by an autocrine/paracrine loop. Overall, there
is no evidence that nicotine itself induces cancer, but nicotine
promotes in vivo the growth of cancer cells and the proliferation of
endothelial cells. This suggests that nicotine after initiation may
contribute to the progression phase of cancer development. Contin-
uation of smoking after lung cancer has been diagnosed should be
discouraged because smoking may not only support tumor growth
but also interferes with treatment.
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This overview aims at providing insight on the acetylcho-line receptor (AchR) pathway in lung cancer. Genome-
wide association studies provide a powerful approach to
identify common, low-penetrance disease loci without prior
knowledge of their location or function.1 Chromosome re-
gions 15q24-25,2,3 15q15.33,4 and 6p21.335 seem to have
common sequence variants that may convey a higher risk for
developing lung cancer. The odds ratios associated with these
variants are generally between 1.2 and 1.5, denoting a definite
but relatively weak association and support the supposition
that susceptibility to lung cancer is polygenic. The 15q24-25
region encompasses the nicotinic acetylcholine receptor sub-
unit genes (nAchR 3, 5, and 4), which play a role in
nicotine addiction.6,7
Two types of AchRs exist. The nAchR and muscarinic
AchR (mAchR). The nAchR is a pentamer consisting of four
related but genetically and immunologically distinct sub-
units. After assembly, the protein contains two  subunits,
and one of each , , and  subunits.8 Although in theory
many different combinations of subunits exists, only a mi-
nority are detected in practice. Factors influencing the assem-
bly are essentially unknown. The nAchR is a Ca or Na
ion channel. The ratio of Ca to Na exchange depends on
the AchR subtype, the 7 subtype has the largest Ca to
Na ratio.
The mAchR receptor belongs to the family of G-protein
coupled receptors with seven transmembrane spanning do-
mains and has five subtypes (M1-M5). Similar to nAchR,
mAchR is also a protein assembled with genetically distinct
subunits. The M1, M3, and M5 subtypes have been linked to
cell proliferation and are coupled with Gq, and on activation
lead to increased levels of intracellularinositol triphosphate,
diacylglycerol, and Ca. The M2 and M4 receptors are
coupled to Gi and inhibit adenylyl cyclase formation.9
People who start smoking at an earlier age run a greater
risk for long-term nicotine addiction. Recently, it was shown
that in three different cohorts of long-term smokers with early
nicotine exposure (before the age of 17 years), the ChRN5-
3-4 haplotypes were related to the severity of nicotine
dependence. Other haplotypes were protective or neutral for
dependence of nicotine.7 The 5-3 subtype nAchR associ-
ation of smoking and lung cancer was specific for lung cancer
because no evidence for elevated risk was found in never
smoking patients with lung cancer or for other smoking-
related cancer types (bladder and kidney).6 The identification
of an age- and smoking-dependent susceptibility haplotype
reinforces the importance of preventing early exposure to
tobacco through public health policies.
BRONCHIAL EPITHELIAL CELLS
Acetylcholine (Ach) is produced and degraded in airway
epithelial cells.10,11 Human bronchial epithelium (HBE) selec-
tively expresses 3, 5, 7, 2, and 4 subunits of the nAchR
genes.12–14 Nicotine and the tobacco-specific nitrosamine,
4-(methylnitrosamino)-1-(-3-pyridine)-1-butanone (NNK), are
agonists for the nAchRs. Remarkably, the affinity of nicotine is
greater than for the physiological agonist, Ach.15
In an epithelial cell culture model, stimulation with
nicotinic derivates (NNK and N-nitrosonornicotine) resulted
in temporary (1–2.5 hours) up-regulation of 7 subunits of
the nAchR14 and in increased proliferative activity.16 The
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increased proliferation was reduced by nicotinic antagonists
(BTX, see later).16 Stimulation with NNK showed in one
study the involvement of signal transduction effectors
STAT1, GATA3, and NFB, whereas N-nitrosonornicotine
activates the first two.16 Nicotine increases activation of AKT
within minutes through.17 Activated AKT increased phos-
phorylation of downstream substrates such as GSK-3,
p70S6K, 4EBP-1, and FKHR.17 This activation by nicotine
was dependent on 3- or 4-containing nAchRs and for NNK
on 7-containing nAchRs.17 The nicotine or NNK concen-
tration required for AKT activation is achievable in smok-
ers.17
Incubation of bronchial epithelial cells with nicotine
produces GM-CSF18 that stimulates inflammatory cells.
Interestingly, apoptosis is induced in nonmalignant hu-
man bronchial epithelial cells treated with damaging agents
such as etoposide, ultraviolet irradiation, or hydrogen perox-
ide. Nicotine or NNK attenuates this apoptotic effect and
results partially in a transformed phenotype manifest as loss
of contact inhibition and loss of dependence on exogenous
growth factors or adherence to extracellular matrix.17
Thus, in epithelial cells, nicotine and NNK have a stim-
ulatory effect on a growth, cell survival, and inflammation.
CANCER
In small cell lung cancer (SCLC) and non-SCLC
(NSCLC), the same nAchR3-5-7-4 subunits as men-
tioned for the HBE cells are expressed.17,19,20 In nonsmokers
with NSCLC, a difference exists in nAchR expression, with
higher expression of nAchR 6-3 subunit genes present in
nonsmokers than in NSCLC from smokers.21 The mAchR is
also expressed in most SCLC and many NSCLC.22 In lung
cancer cells, nicotine and NNK bind to nAchR,23 whereas
nicotine binds also to mAchR.24 In NSCLC cell lines, nico-
tine leads to an increase in 7-nAchRs.25
Loop
Both NSCLC and SCLC cell lines synthesize and
release Ach.26 In squamous cell carcinoma (SqCC), the en-
zyme choline acetyltransferase is strongly up-regulated,
whereas cholinesterases are down-regulated.27,28 This combi-
nation causes prominent increase in Ach content in SqCC
compared with normal lung.28 The mechanism underlying the
increased cholineacetyltransferase expression in SqCC is not
clear, although nicotine itself stimulates Ach secretion.28 In
SCLC, mAchR and Ach are coexpressed.22 Increased levels
of Ach provide endogenous proliferative stimuli to both
mAchR and nAchR. These findings suggest that an autocrine or
a paracrine cholinergic pathway for mAchR and nAchR in
SCLC and for nAchR in NSCLC exists see Figure 1.
Modulator of Receptor Activity
Lynx1 is a member of a newly described family of
allosteric modulators of nicotinic receptor activity. It has
been shown to attenuate responses to Ach and to increase the
extent to which Ach and nicotine desensitize nAchR.28
Lynx1, the nAchR accessory protein, is expressed in normal
bronchial epithelium.29 In SqCC, Lynx1 is expressed at
significantly lower levels.28 Therefore, decreases in Lynx1
may lead to potentiate responses to exogenous nicotine and
endogenous Ach.
Proliferation
In lung cancer, nicotine induces proliferation of tumor
cells by binding to the 7-nAchR. In this pathway, activation
of SRC and Rb-Raf-1/pERK/p90RSK is involved.30,24 Stim-
ulation with nicotine induces a Ca influx within sec-
onds, which may last for 15 min.31,32 Nicotine stimulates
tumor growth in a murine model where A549 cells ortho-
topically grafted.24 Inhibitors of nicotine at the level of
7-nAchR (-bungarotoxin and -cobratoxin) suppress
this proliferative effect, suggesting that nAchRs control the
rate of proliferation.24,33
Stimulation of the mAchR in SCLC induced Ca re-
lease, MAPK, and AKT activation, which is associated with
proliferation. Blocking experiments (antagonists and siRNA)
showed that M3 subtype was responsible for Ca release and
reduced MAPK, AKT, and inhibited proliferation.22
Nicotine induces an increase in fibronectin produc-
tion.25 Extracellular fibronectin binds to 51 integrin, which
subsequently leads to increased proliferation through ERK,
PI3-K, and mTOR pathways. This indirect proliferative effect
of nicotine is maximal at days 4 to 525 and could be blocked
at the level of the 51 integrin receptor. These data show
that nicotine has a direct short term and an indirect longer
term effect on proliferation.
Apoptosis
Similar to the effect in HBE, nicotine diminishes apo-
ptosis in SCLC and NSCLC cell lines.34–36 The antiapoptotic
effects of nicotine were mediated by nAchR-3 and required
the AKT pathway, leading to an increased recruitment of
E2F1 and concomitant dissociation of retinoblastoma tumor
suppressor protein. The binding of E2F1 to the promoter of
survivin and XIAP genes resulted in the up-regulation of
these inhibitors of apoptosis.35 7-nAchR antagonists inhib-
ited proliferation of NSCLC through mitochondria-associated
apoptosis.36 Thus, nicotine has a prolonged effect on tumor
cell survival by preventing apoptosis.
Invasion
Pathways that contribute to the proinvasive effects of
nicotine include 7-nAchR-mediated activation of Src, cal-
cium channels, and up-regulation of EGFR. Nicotine induced
down-regulation of epithelial markers, E-cadherin and -cate-
nin, whereas it caused concomitant increase of mesenchymal
proteins fibronectin and vimentin in A549 human NSCLC.37
These effects are part of the proinvasive epithelial-mesenchy-
mal transition phenomenon.
Moreover, fibronectin may confer resistance to apopto-
sis induced by chemotherapy as has been shown in SCLC.38
Beside the effect on fibronectin, nicotine also stimulated
HIF-1, with subsequent increase in VEGF, stimulating an-
giogenesis and invasion.39 These data demonstrate proinva-
sive and angiogenic effects of nicotine.
Survival
In patients diagnosed with smoking-related lung cancer
and who continue smoking, a negative correlation with lung
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cancer survival has been shown.40–42 The reduced treatment
efficacy may be well explained by the pluriform effect of
nicotine on tumor cell proliferation, apoptosis, epithelial-
mesenchymal transition, proinvasive, and angiogenic effects,
which are reenforced by the autocrine or paracrine loop.
Possible Treatment Options
These effects of nicotine in lung cancer raise the ques-
tion whether inhibition of 7-nAchR activity by nontoxic
agents or inhibition of its downstream mediators might open
novel avenues for the therapy for cancers promoted by
smoking.37 Members of the type II -neurotoxin subfamily
have high affinity for 7-nAchR. Examples are -CbT and
-bungarotoxin.36,39 The latter acts as an antagonist to both
7-nAchR and mAchR.
Although treatment with nicotinic receptor antagonists
can have significant effects on blood pressure, mAchR an-
tagonists are better tolerated and are widely used for treat-
ment of chronic obstructive pulmonary disease.43 Therefore,
it is not excluded that muscarinic antagonists might serve as
a useful adjuvant to conventional chemotherapeutic regimens
for SCLC and NSCLC, which express the autocrine cholin-
ergic loop.
Overall, there is no evidence that nicotine itself induces
cancer, but nicotine promotes in vivo the growth of cancer
cells and the proliferation of endothelial cells. This suggests
that nicotine after initiation may contribute to the progression
phase of cancer development. Continuation of smoking after
lung cancer has been diagnosed should be discouraged be-
cause smoking may not only support tumor growth but also
interferes with treatment.
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